Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Incyte

< Previous 1 2 3 4 5 Next >
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Tickers INCY
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Tickers INCY
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Tickers INCY
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025
From Incyte
Via Business Wire
Tickers INCY
Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Incyte
Via Business Wire
Tickers INCY
Incyte to Report First Quarter Financial Results
From Incyte
Via Business Wire
Tickers INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Tickers INCY
Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
From Incyte
Via Business Wire
Tickers INCY
Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting
From Incyte
Via Business Wire
Tickers INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Tickers INCY
Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
Tickers INCY
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Tickers INCY
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones
From Incyte
Via Business Wire
Tickers INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Tickers INCY
Incyte to Report Fourth Quarter and Year-End 2024 Financial Results
From Incyte
Via Business Wire
Tickers INCY
Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
From Incyte
Via Business Wire
Tickers INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Tickers INCY
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Tickers INCY
Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
From Incyte
Via Business Wire
Tickers INCY
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
From Incyte
Via Business Wire
Tickers INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Tickers INCY
Incyte Announces Updated Presentation Time for Upcoming Investor Conference
From Incyte
Via Business Wire
Tickers INCY
Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting
From Incyte
Via Business Wire
Tickers INCY
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs
From Incyte
Via Business Wire
Tickers INCY
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Tickers INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Tickers INCY
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Tickers INCY
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Tickers INCY
Incyte Named One of Top 5 Companies on Science Magazine’s 2024 Top Employers List
From Incyte
Via Business Wire
Tickers INCY
Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program
From Incyte
Via Business Wire
Tickers INCY
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.